西非埃博拉病毒病疫情期间临床研究的荟萃分析证实需要随机对照组
该荟萃分析比较了2013-2016年西非埃博拉病毒病疫情期间六项临床研究的非随机对照组共1147例感染者,发现各对照组死亡率差异较大(31%至66%),且调整预后变量后异质性仍未消除,提示非随机对照组间缺乏同质性,难以替代随机对照。
要点
- 六项研究的非随机对照组共纳入1147例埃博拉病毒感染者,死亡率范围为31%至66%。
- 调整年龄、性别和循环阈值后,非随机对照组间的异质性仍然存在。
- 非随机对照组间缺乏同质性,比较非随机对照组与实验治疗组可能得出无效结论。
核心结论
- 非随机对照组间存在相当大的异质性,调整预后变量后仍未消除,比较非随机对照组与实验治疗组可能得出无效结论。
研究设计与样本
- 荟萃分析,评估2013-2016年西非埃博拉病毒病疫情期间六项临床研究的非随机对照组,共1147例埃博拉病毒感染者。
主要发现
- 六项研究的非随机对照组死亡率范围为31%至66%。
- 调整基线协变量(年龄、性别和循环阈值)的统计模型未能充分重新校准这些研究,异质性仍然存在。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent Ebola virus disease outbreaks affirm the dire need for treatments with proven efficacy. Randomized controlled clinical trials remain the gold standard but, during disease outbreaks, may be difficult to conduct due to ethical concerns and challenging field conditions. In the absence of a randomized control group, statistical modeling to create a control group could be a possibility. Such a model-based reference control would only be credible if it had the same mortality risk as that of the experimental group in the absence of treatment. One way to test this counterfactual assumption is to evaluate whether reasonable similarity exists across nonrandomized control groups from different clinical studies, which might suggest that a future control group would be similarly homogeneous. We evaluated similarity across six clinical studies conducted during the 2013-2016 West Africa outbreak of Ebola virus disease. These studies evaluated favipiravir, the biologic ZMapp, the antimalarial drug amodiaquine, or administration of convalescent plasma or convalescent whole blood. We compared the nonrandomized control groups of these six studies comprising 1147 individuals infected with Ebola virus. We found considerable heterogeneity, which did not disappear after statistical modeling to adjust for prognostic variables. Mortality risk varied widely (31 to 66%) across the nonrandomized control arms of these six studies. Models adjusting for baseline covariates (age, sex, and cycle threshold, a proxy for viral load) failed to sufficiently recalibrate these studies and showed that heterogeneity remained. Our findings highlight concerns about making invalid conclusions when comparing nonrandomized control groups to cohorts receiving experimental treatments.
引用
- Dodd LE, Follmann D, Proschan M, et al. A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. Sci Transl Med. 2019. PMID: 31776287. doi:10.1126/scitranslmed.aaw1049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。